These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

768 related items for PubMed ID: 19395543

  • 1. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loët X, Tharasse C, Vittecoq O.
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [Abstract] [Full Text] [Related]

  • 2. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.
    J Med Econ; 2012 Jul; 15(6):1054-63. PubMed ID: 22563743
    [Abstract] [Full Text] [Related]

  • 3. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R, Kragballe K, Dam TN, Skov L.
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [Abstract] [Full Text] [Related]

  • 4. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [Abstract] [Full Text] [Related]

  • 5. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P.
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [Abstract] [Full Text] [Related]

  • 6. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J.
    Arthritis Rheum; 2007 May 15; 57(4):639-47. PubMed ID: 17471540
    [Abstract] [Full Text] [Related]

  • 7. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É, Houvenagel É, Goëb V, Fouache D, Martin A, Le Dantec P, Dernis E, Wendling D, Ansemant T, Berthelot JM, Bader-Meunier B, Kantelip B, Le CRI.
    Joint Bone Spine; 2012 Oct 15; 79(5):457-63. PubMed ID: 22088934
    [Abstract] [Full Text] [Related]

  • 8. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug 15; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 9. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr 15; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 10. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR.
    J Am Acad Dermatol; 2012 Nov 15; 67(5):e179-85. PubMed ID: 21752492
    [Abstract] [Full Text] [Related]

  • 11. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul 15; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 12. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug 15; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 13. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN, Battafarano DF.
    Semin Arthritis Rheum; 2010 Dec 15; 40(3):233-40. PubMed ID: 20580412
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
    Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, Dougados M.
    Ann Rheum Dis; 2006 Dec 15; 65(12):1631-4. PubMed ID: 16901960
    [Abstract] [Full Text] [Related]

  • 15. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
    Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM.
    Rheumatology (Oxford); 2006 Sep 15; 45(9):1121-4. PubMed ID: 16510526
    [Abstract] [Full Text] [Related]

  • 16. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
    Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA.
    Scand J Rheumatol; 2009 Sep 15; 38(5):328-31. PubMed ID: 19579151
    [Abstract] [Full Text] [Related]

  • 17. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.
    Adv Ther; 2012 Mar 15; 29(3):234-48. PubMed ID: 22411424
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.
    Dermatology; 2012 Mar 15; 225(4):312-9. PubMed ID: 23295383
    [Abstract] [Full Text] [Related]

  • 19. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 15; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 20. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
    Lim LL, Fraunfelder FW, Rosenbaum JT.
    Arthritis Rheum; 2007 Oct 15; 56(10):3248-52. PubMed ID: 17907169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.